GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

RKDA · Mar 31, 2024

Arcadia Biosciences, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0000950170-24-058563General Corporate
Capex intensity70thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

1.04% · OPTIONAL · VALID

Operating cash generation40thOwn-history percentile · N=10
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-255.78% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

-16.83% · CORE · NOT_ENOUGH_HISTORY

Inventory pressure50thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

145.90% · OPTIONAL · VALID

Gross margin78thOwn-history percentile · N=9
Evidence method

Level · gp.fundamentals.gross_margin

34.66% · CORE · VALID

Operating margin50thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.operating_margin

-244.14% · CORE · VALID

R&D intensity50thOwn-history percentile · N=10
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

21.67% · OPTIONAL · VALID

SBC intensity30thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

11.00% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History19 statesSelf-history eligible
Dec 31, 20210/7 normalizedLevel 3Mar 31, 20220/7 normalizedLevel 3Jun 30, 20220/7 normalizedLevel 3Sep 30, 20220/8 normalizedLevel 3Dec 31, 20220/8 normalizedLevel 3Mar 31, 20230/8 normalizedLevel 3Jun 30, 20230/8 normalizedLevel 3Sep 30, 20236/8 normalizedLevel 3Dec 31, 20237/8 normalizedLevel 3Mar 31, 20247/8 normalizedLevel 3Jun 30, 20247/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20267/7 normalizedLevel 4
Period transition

What moved in the state?

Capex Intensity Increased
Previous
0.09%
Current
1.04%
Delta
0.94%
Cash Generation Increased
Previous
-286.94%
Current
-255.78%
Delta
31.16%
Growth Increased
Previous
-46.46%
Current
-16.83%
Delta
29.63%
Inventory Pressure Increased
Previous
36.74%
Current
145.90%
Delta
109.16%
Margin Decreased
Previous
38.09%
Current
34.66%
Delta
-3.42%
Profitability Increased
Previous
-261.50%
Current
-244.14%
Delta
17.36%
R And D Intensity Decreased
Previous
26.02%
Current
21.67%
Delta
-4.35%
Sbc Intensity Decreased
Previous
13.45%
Current
11.00%
Delta
-2.46%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · RKDA Fundamental State →Analogous To · RKDA state analogue 5 →Has State · Arcadia Biosciences, Inc. →Transitioned To · RKDA Fundamental State →Transitioned To · RKDA CAPEX_INTENSITY_INCREASED →Transitioned To · RKDA CASH_GENERATION_INCREASED →Transitioned To · RKDA GROWTH_INCREASED →Transitioned To · RKDA INVENTORY_PRESSURE_INCREASED →Transitioned To · RKDA MARGIN_DECREASED →Transitioned To · RKDA PROFITABILITY_INCREASED →Transitioned To · RKDA R_AND_D_INTENSITY_DECREASED →Transitioned To · RKDA SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.